Company news

Hemab Therapeutics Holdings, Inc. news in 2026

Hemab Therapeutics Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Hemab Therapeutics to Participate in Upcoming Investor Conferences

November 11, 2026

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 10, 2026

Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia

November 9, 2026

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

November 4, 2026

Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026

November 3, 2026

Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert

September 24, 2026

Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding

September 17, 2026

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

July 13, 2026

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

July 11, 2026

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

Hemab Therapeutics Reports First Quarter 2026 Financial Results

May 21, 2026

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 4, 2026

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

April 30, 2026

Calls in 2026